Sharemaestro company-news research for Alto Neuroscience, Inc. (ANRO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Provisional evidence
Company news sentiment
Latest ANRO news and sentiment
Alto Neuroscience, Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
11 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone41/100
→
Published 30-day score49/100
Latest source headline
At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares.
Stock Titan · 05 Oct 2026 20:59
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
11 current stories are mapped specifically to ANRO.
The score uses 5 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.094.
Confidence is 20/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
100%/100
Company news11 company stories
99/100
Story agreement1/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.094 after freshness weightingSource breadth100
5 independent publishersCompany relevance100
share tied directly to this companyFreshness35
recency-weighted evidenceAgreement99
how closely stories agreePublisher mix63
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202648USD 24.8-6.4%
25 Sep 202650USD 26.49-12.5%
18 Sep 202650USD 30.27-5.4%
11 Sep 202650USD 32.0-10.0%
04 Sep 202650USD 35.55+1.2%
28 Aug 202649USD 35.13+2.5%
21 Aug 202656USD 34.28+6.7%
14 Aug 202657USD 32.14+12.1%
Provisional evidence
News subjects
What is shaping the score
Market update4510 stories · 91%
Analyst action421 stories · 9%
Source mix
Where the evidence comes from
Stock Titan463 stories · 27%
Moomoo432 stories · 18%
TradingView401 stories · 9%
Investing.com421 stories · 9%
Investing.com Nigeria501 stories · 9%
www.marketscreener.com501 stories · 9%
Investing.com Canada501 stories · 9%
Recurring subjects
Subjects appearing most often
Life Sciences10Finance7Financial Markets5Earnings3IPO1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral07 Oct 21:50
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Oct 21:50 | 49 | +0 | 20/100 (-4) | 11 (0) | Provisional |
| 05 Oct 23:59 | 49 | +1 | 24/100 (-6) | 11 (+1) | Provisional |
| 03 Oct 23:59 | 48 | +0 | 30/100 (-3) | 10 (+1) | Provisional |
| 02 Oct 23:59 | 48 | -2 | 33/100 (+18) | 9 (+5) | Provisional |
| 29 Sep 23:59 | 50 | +0 | 15/100 (-1) | 4 (-4) | Provisional |
| 21 Sep 23:59 | 50 | +0 | 16/100 (-11) | 8 (-6) | Provisional |
| 14 Sep 23:59 | 50 | +0 | 27/100 (+11) | 14 (-15) | Provisional |
| 09 Sep 23:59 | 50 | +1 | 16/100 (-8) | 29 (-8) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 11 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action1 story
56.6%0.0%
Market update3 stories
43.4%0.0%
Each side uses the same scale: 0–56.6% of the retained directional evidence.
Where the influence comes from
56.6%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares.
Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options for 55,000 common shares at $2.32 per share on October 2, 2026. This transaction increased his direct holdings to 79,060 common shares, while he still holds 57,405 options. The options had a vesting schedule t…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options for 55,000 common shares at $2.32 per share on October 2, 2026. This transaction increased his direct holdings to 79,060 common shares, while he still holds 57,405 options. The options had a vesting schedule that began in September 2022, with monthly installments thereafter, contingent on continuous service.
- Published
- 05 Oct 2026 20:59
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
40/100 tone
An insider at Alto Neuroscience recently sold shares totaling $3,567,247. This transaction was disclosed in a recent SEC filing. The sale indicates a significant divestment by a company insider.
18.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
An insider at Alto Neuroscience recently sold shares totaling $3,567,247. This transaction was disclosed in a recent SEC filing. The sale indicates a significant divestment by a company insider.
- Published
- 03 Oct 2026 03:58
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 18.4% of directional evidence · 6.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
FinanceLife Sciences
42/100 tone
Nicholas Conrad Smith, President and CFO of Alto Neuroscience (NASDAQ:ANRO), sold approximately $3.57 million in common stock while simultaneously acquiring shares worth $316,982 through exercising employee stock options. These transactions, executed under a 10b5-1 trading plan, occurred …
56.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Nicholas Conrad Smith, President and CFO of Alto Neuroscience (NASDAQ:ANRO), sold approximately $3.57 million in common stock while simultaneously acquiring shares worth $316,982 through exercising employee stock options. These transactions, executed under a 10b5-1 trading plan, occurred after ANRO shares surged significantly over the past year, though the stock is currently considered overvalued. The company also recently announced a $100 million stock offering and received a raised price target from H.C. Wainwright following positive development plan updates.
- Published
- 02 Oct 2026 23:59
- News subject
- Analyst action
- Why this score
- Institutional or insider selling, Dilution risk, Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 56.6% of directional evidence · 6.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife SciencesFinanceIPO
—Unscored
Market updateNot used in direction
Alto Neuroscience(ANRO.US) Officer Sells US$3.57 Million in Common Stock
An officer at Alto Neuroscience (ANRO.US) has sold common stock valued at $3.57 million. This transaction indicates a significant insider sale at the company.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
An officer at Alto Neuroscience (ANRO.US) has sold common stock valued at $3.57 million. This transaction indicates a significant insider sale at the company.
- Published
- 02 Oct 2026 12:35
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com
This article reports on a Form 4 filing for Alto Neuroscience Inc. for October 1st, published by Investing.com. The piece is brief, primarily serving as an announcement of the filing without providing additional details on its content or implications. It is dated October 2, 2026, at 03:36.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article reports on a Form 4 filing for Alto Neuroscience Inc. for October 1st, published by Investing.com. The piece is brief, primarily serving as an announcement of the filing without providing additional details on its content or implications. It is dated October 2, 2026, at 03:36.
- Published
- 02 Oct 2026 03:25
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
EarningsFinanceFinancial MarketsLife Sciences
40/100 tone
Nicholas Conrad Smith, President and CFO of Alto Neuroscience (ANRO), sold shares worth over $3.5 million under a Rule 10b5-1 plan. The sales occurred at weighted average prices between $25.7786 and $26.87 per share. Following these transactions, Smith directly owns 24,060 shares of Alto …
12.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Nicholas Conrad Smith, President and CFO of Alto Neuroscience (ANRO), sold shares worth over $3.5 million under a Rule 10b5-1 plan. The sales occurred at weighted average prices between $25.7786 and $26.87 per share. Following these transactions, Smith directly owns 24,060 shares of Alto Neuroscience common stock.
- Published
- 02 Oct 2026 01:25
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 12.5% of directional evidence · 7.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options to acquire 134,886 common shares at $2.35 per share on September 29 and 30, 2026, and subsequently sold all of these shares across the same dates. The sales, totaling approximately $3.57 million gross proceeds…
12.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options to acquire 134,886 common shares at $2.35 per share on September 29 and 30, 2026, and subsequently sold all of these shares across the same dates. The sales, totaling approximately $3.57 million gross proceeds, were executed under a Rule 10b5-1 trading plan adopted on June 30, 2026. This transaction resulted in a pre-tax spread of approximately $3.25 million for Smith.
- Published
- 02 Oct 2026 01:25
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 12.5% of directional evidence · 7.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Stock options underpin an officer's proposed share sale at Alto Neuroscience (NYSE: ANRO).
Nicholas Smith, an officer at Alto Neuroscience (ANRO), has filed a Form 144 notice proposing to sell 134,886 common shares with an aggregate market value of over $3.59 million. The proposed sale, scheduled for September 29, 2026, is tied to the exercise of stock options over the next thr…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Nicholas Smith, an officer at Alto Neuroscience (ANRO), has filed a Form 144 notice proposing to sell 134,886 common shares with an aggregate market value of over $3.59 million. The proposed sale, scheduled for September 29, 2026, is tied to the exercise of stock options over the next three months. This filing indicates that the shares will be acquired and paid for on the dates of their exercise and subsequent sale on the NYSE.
- Published
- 29 Sep 2026 20:34
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Global BMI Index
Alto Neuroscience, Inc. (NYSE: ANRO) has been added to the S&P Global BMI Index. This announcement follows several other recent updates for the company, including executive promotions and price target adjustments from analysts. Alto Neuroscience is a clinical-stage biopharmaceutical compa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Alto Neuroscience, Inc. (NYSE: ANRO) has been added to the S&P Global BMI Index. This announcement follows several other recent updates for the company, including executive promotions and price target adjustments from analysts. Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing personalized treatments for mental health conditions using its Precision Psychiatry Platform.
- Published
- 21 Sep 2026 21:49
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Alto Neuroscience at H.C. Wainwright: pipeline breadth gains focus By Investing.com
Alto Neuroscience presented its broad clinical-stage strategy in psychiatry at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting its lead program ALTO-207 for treatment-resistant depression and two other Phase 2B programs, ALTO-300 and ALTO-100. The company emphas…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Alto Neuroscience presented its broad clinical-stage strategy in psychiatry at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting its lead program ALTO-207 for treatment-resistant depression and two other Phase 2B programs, ALTO-300 and ALTO-100. The company emphasizes a precision psychiatry approach using biomarkers to identify responsive patients and improve trial efficiency. Management also discussed a strong financial position, upcoming data readouts in 2027, and efforts to enhance trial quality by addressing "professional patient" risks.
- Published
- 14 Sep 2026 13:57
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 09 Sep 2026 12:03
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Earlier company news
ANRO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 66 older ANRO headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ANRO, but the headline and available text are not mainly about Alto Neuroscience, Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ANRO sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.